Research Use Only: What It Actually Means, and What It Does Not Protect

The four words most peptide sellers misunderstand

Search any research peptide catalogue and you will find the same four words near the bottom of the page: for research use only. Ask the person running that catalogue what those words do for them, and you will usually get a version of the same answer. They are the shield. They are what keeps the operation on the right side of the line.

That answer is wrong, and the way it is wrong matters, because it points the whole compliance effort at the wrong thing. Sellers spend enormous attention on where the disclaimer sits and almost none on the sentences that actually determine their regulatory exposure.

This is not a legal opinion and nobody should treat it as one. It is a reading of the primary regulatory text, with links so you can check every claim against the source rather than against anyone's summary, including this one.

Where the phrase actually comes from

The exact wording that circulates in this industry is not folklore. It appears in the Code of Federal Regulations, and it has a specific home.

Title 21, section 809.10 governs the labeling of in vitro diagnostic products. Buried in subsection (c) is a requirement that certain products not yet shown to be effective must carry a prominent statement, and the text specifies it verbatim: for research use only, not for use in diagnostic procedures. You can read the provision yourself in the Code of Federal Regulations (CFR), at 21 CFR 809.10.

Read that sentence again, because the second half is the part that almost never survives the trip into a peptide catalogue. The full phrase is about diagnostic procedures. It is a labeling rule for products used to test specimens. It is not a general category of goods, it is not an exemption, and it does not appear anywhere in the regulations as a status that a substance can be placed into in order to sit outside drug law.

Research use only (RUO) peptides became a category this way. An entire industry took half a sentence from an in vitro diagnostics labeling rule and made it into a legal category. That is the origin of the confusion, and once you see it, the rest follows.

What actually determines whether you are selling a drug

The provision that governs your exposure is somewhere else entirely, and it is short enough to read in a minute.

Title 21, section 201.128 defines what intended use means. The operative language is that intended use refers to the objective intent of the persons legally responsible for the labeling of an article, and that this intent may be shown by the person's expressions, by the design or composition of the article, or by the circumstances surrounding its distribution. It then gives examples: labeling claims, advertising matter, or oral or written statements. The full text is at 21 CFR 201.128.

Sit with what that establishes. Intended use is not something you declare. It is something a regulator infers from what you said and did. Your disclaimer is one input. Your product page is another. So is your email sequence, your affiliate's video script, your reply in a support ticket, and what your founder said on a podcast.

Put the two provisions side by side and the picture is unambiguous. The RUO phrase governs how a diagnostic product is labeled. Section 201.128 governs what your whole body of communication establishes about what your product is for. The second one is not cancelled by the first.

A disclaimer at the bottom of a page that spends eight hundred words describing how a compound helps a person is not a defence. It is a piece of evidence sitting next to a much larger pile of contrary evidence, and the pile is what gets read.

The sentences that quietly establish intent

Here is the practical version. These are the places where operators establish objective intent without ever writing a sentence they would recognise as a claim.

• The call to action. A button that invites a reader to begin a protocol is inviting them to begin a regimen. The word is doing work, and it is doing it on a transactional button, which is the worst possible place for it.

• The consultation offer. Offering to advise a buyer on what to select for their situation describes an advisory relationship about a personal outcome.

• The mission statement. Positioning a company around human optimisation attaches a personal outcome to a catalogue of compounds. A mission statement is still advertising.

• The support reply. A written answer to a customer question is a written statement by a person responsible for the labeling. Section 201.128 names oral or written statements specifically.

• The affiliate script. You did not write it, but the claim it conveys is yours. A creator saying it does not make it someone else's representation.

• The category page. Grouping compounds under a heading that names a bodily outcome does the same work as a sentence, without a verb.

None of those requires the word treat. Each of them is the kind of circumstance the regulation describes.

The FTC problem runs on a separate track

Operators who get the FDA question right often still lose on the second front, because they assume the two agencies are asking the same question. They are not.

The Federal Trade Commission's Health Products Compliance Guidance sets a substantiation standard that applies whether or not your FDA posture is sound. The guidance states that claims about the benefits of health-related products require substantiation in the form of competent and reliable scientific evidence. It then goes further, and this is the sentence that catches most catalogues: as a general matter, substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing.

Read what that does to a peptide catalogue. The overwhelming majority of the published work behind these compounds is preclinical: animal models, cell culture, mechanism studies. That work is real and it is interesting, and under this standard it does not substantiate a benefit claim about a person. Not because the science is bad, but because it is not the kind of evidence the standard asks for.

Two further points from the same guidance are worth internalising.

First, the guidance defines advertising to cover not only traditional ads but the wide variety of marketing techniques and promotion methods that marketers engage in. There is no channel that sits outside it.

Second, substantiation has to exist at the time the claim is made. Assembling a citation list after a letter arrives is not substantiation, it is a response to having been caught without any.

What a defensible position actually looks like

None of this means the business is impossible. It means the defensible version is built differently, and the differences are specific.

Report findings in their own terms. There is a real distinction between describing what a study observed and asserting a benefit. In a rat model, accelerated tendon healing was observed by the authors is a defensible sentence about published work. It carries its model system with it, which is precisely what makes it honest. The version that drops the rat is a different claim entirely.

Keep the catalogue and the science in separate rooms. A compound is a molecule and the literature about it is true regardless of who sells it. A product is a sellable unit with a price and a pack size. When those merge on one page, a neutral statement about published research becomes a reason to add to cart, and the merge is what converts it into a claim.

Make the factual claims the ones you can actually prove. Purity is a factual representation. So is third-party tested. Both attach to a batch, not to a brand, which means a site-wide purity figure needs per-batch documentation behind it. This is the most checkable claim on most peptide sites and therefore the easiest one to be caught on. It is also the easiest to get right, because it is entirely within your control: name the testing laboratory, hold the certificate for the batch that is shipping, and be able to produce it when someone asks.

Read the enforcement record. The FDA publishes warning letters in a searchable index. It is the cheapest signal available about which specific phrasings draw attention, and almost nobody in this category reads it on a schedule. Monthly is enough.

Look up approval status rather than asserting it. Whether any specific molecule is an approved drug product is a question with an authoritative answer in Drugs@FDA. Confident recall is not a source, and the lookup takes less time than the sentence you were about to write.

The disclaimer still matters, for a narrower reason

Nothing above argues for removing your disclaimer. Keep it, and keep it accurate.

Where the dietary supplement provisions apply, the disclaimer text is not something you paraphrase. Title 21, section 101.93 prescribes exact wording and requires it be placed adjacent to the statement it qualifies, with no intervening material or a linking symbol. The provision is at 21 CFR 101.93. A rewritten disclaimer in a footer satisfies neither the wording requirement nor the placement one.

But understand what the disclaimer is doing. It is a floor. It is not a licence for stronger copy above it, and a prohibited claim in a headline is not rescued by fine print underneath. The question a regulator asks is what the page conveys to a reasonable reader taken as a whole, and no reasonable reader weights the footer against the headline.

What to change this week

If you run a catalogue in this category, three things are worth doing in the next seven days, and none of them requires a lawyer to start.

• Audit your calls to action, not your disclaimer. Read every button, every subject line and every heading. Any one of them that invites a person to begin something, or offers to advise them on their situation, is establishing intent. Rewrite those first, because they are short, they are few, and they are the highest-exposure text on the site.

• Find your factual claims and check whether you can prove them. Every purity percentage, every testing claim, every superlative. For each one, ask whether the document that substantiates it exists and whether you could produce it today. The ones that fail come down until they do.

• Read one month of warning letters. Not to become a lawyer, but to calibrate. Twenty minutes will teach you more about which sentences attract attention than any summary, including this one.

Then bring it to counsel. The point of doing the three items first is that you arrive with a specific list rather than a general anxiety, and the conversation costs a fraction of what it otherwise would.

Frequently asked questions

Does labeling a product for research use only make it legal to sell?

No. The phrase originates in an in vitro diagnostics labeling provision at 21 CFR 809.10 and is not a general exemption. What determines your position is intended use under 21 CFR 201.128, which a regulator infers from your labeling claims, advertising, and written or oral statements.

If the science is real, can I describe it?

Yes, in its own terms. Describing what a published study observed, with the model system stated, is different from claiming a benefit. The FTC substantiation standard is what separates them: a benefit claim about people generally requires randomized controlled human testing, which most preclinical work is not.

Do support tickets and affiliate videos count as advertising?

Yes. The FTC guidance defines advertising to include the wide variety of marketing techniques and promotion methods marketers engage in, and 21 CFR 201.128 names oral or written statements explicitly. There is no private channel.

Is a purity claim safe if my supplier tells me the number?

Not on its own. Purity is a factual representation that attaches to a specific batch. A supplier's verbal assurance is not documentation, and the claim is yours once you publish it.

Is this legal advice?

No. This is a reading of primary regulatory text with links to every source so you can verify it independently. It is an operational aid for deciding what to review, not a substitute for qualified counsel, and anything touching your specific circumstances should go to a lawyer.

Sourcing research compounds

Every compound referenced in this article is supplied strictly for laboratory research purposes only. Nothing here is for human consumption, and nothing here is intended to diagnose, treat, cure, or prevent any disease.

For catalogue specifications, batch documentation and current availability, see the Olympus Peptide Labs catalogue.